You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage IIIB–IVM1c melanoma

 

Online download statistics by month:

Online download statistics by month: March 2021 to March 2024

AbstractFullPdf
Mar 202110410451
Apr 2021356357173
May 2021163163113
Jun 202111811843
Jul 202111211349
Aug 2021767647
Sep 2021646530
Oct 2021838344
Nov 2021828346
Dec 2021848646
Jan 2022707333
Feb 2022646642
Mar 2022646453
Apr 2022707024
May 2022879152
Jun 2022616132
Jul 2022666727
Aug 2022464615
Sep 2022485033
Oct 2022586042
Nov 2022434549
Dec 2022353514
Jan 2023414222
Feb 2023484916
Mar 2023676722
Apr 2023252632
May 2023292915
Jun 2023343410
Jul 2023303013
Aug 2023474723
Sep 2023464615
Oct 202313913919
Nov 202322922920
Dec 2023434318
Jan 2024343528
Feb 2024353724
Mar 2024515186
Total285228801421